1. Home
  2. Medical News
  3. Oncology
advertisement

Low Muscle Index Linked to Survival in Atezolizumab-Treated ES-SCLC

Simplified lung illustration showing a subtle small cell lung cancer lesion against a neutral clinical background
11/20/2026

Key Takeaways

  • In a single-center cohort receiving first-line carboplatin, etoposide, and atezolizumab for ES-SCLC, Martin-defined low SMI was associated with shorter adjusted OS.
  • Higher albumin and lower LDH were associated with lower mortality in the primary adjusted analysis.
  • Alternative SMI cutoffs and continuous SMI did not show significant OS associations.
  • The low-SMI association varied over follow-up, while adjusted PFS was not significantly associated with low SMI.
Survival trajectories differ among patients with extensive-stage small-cell lung cancer (ES-SCLC), even when they receive the same first-line carboplatin, etoposide, and atezolizumab regimen. Baseline muscle quantity on staging scans and routine blood measurements may capture different aspects of a patient’s condition, but it's unclear how those measures relate to survival with this regimen.

Investigators retrospectively assessed an atezolizumab-treated extensive-stage small-cell lung cancer cohort of 81 patients starting first-line carboplatin, etoposide, and atezolizumab at a single center in Denizli, Türkiye, between May 2019 and January 2026; all had Eastern Cooperative Oncology Group (ECOG) performance status 0–1. Skeletal muscle area at the third lumbar vertebra (L3) was measured on the low-dose computed tomography (CT) component of baseline fluorine-18 fluorodeoxyglucose positron emission tomography/CT (FDG PET/CT). Area normalized to height squared yielded skeletal muscle index (SMI). Martin primary low-SMI criteria were sex-specific and, for men, stratified by body mass index (BMI); investigators also examined Prado and small-cell lung cancer–specific cutoffs and continuous SMI. Overall survival (OS) ran from treatment start to death, and exploratory progression-free survival (PFS) ran from treatment start to progression or death. The primary adjusted OS model included age, Martin-defined low SMI, albumin per 5 g/L increase, and lactate dehydrogenase (LDH) per doubling. Analyses used available cases without imputation.

Martin criteria classified 33 of 80 assessable patients (41.3%) as having low SMI. Median OS was 8.48 versus 14.26 months in the low- and normal-SMI groups, respectively. The unadjusted log-rank comparison yielded p = 0.050.

After adjustment, Martin-defined low SMI was associated with higher mortality: hazard ratio (HR), 2.03; 95% confidence interval (CI), 1.07–3.86; p = 0.030. Higher albumin was associated with lower mortality, whereas higher LDH was associated with higher mortality. The low-SMI association persisted after post hoc adjustment for bone metastases, although the LDH association attenuated. Neither alternative categorical definitions nor continuous SMI showed significant OS associations. Post hoc time-dependent estimates suggested a stronger low-SMI association later in follow-up, but were imprecise. Low SMI was not significantly associated with adjusted PFS; higher LDH was associated with shorter PFS.

The retrospective, single-center cohort was modest and predominantly male, limiting assessment of female-specific cutoffs. Muscle quantity was measured only at baseline; metastatic-site, radiotherapy, and response data were incomplete, and segmentation reproducibility was not formally evaluated. Unmeasured functional status, weight loss, comorbidity, or disease burden could confound the OS association. Proportional-hazards diagnostics suggested that the low-SMI association changed with time, while bone adjustment and time-specific modeling were post hoc. Toxicity and post-progression survival were not evaluated. The prognostic association does not establish that SMI predicts atezolizumab benefit or that changing treatment or muscle mass changes survival.

The authors concluded that Martin-defined low SMI, albumin, and LDH tracked OS, but that cutoff dependence, time variation, and the absence of a low-SMI PFS association temper interpretation. They called for larger multicenter evaluation using standardized imaging.

Clinician Questions

Can a low skeletal muscle index on PET/CT diagnose sarcopenia in extensive-stage small-cell lung cancer?

No. Baseline L3 SMI from PET/CT measured muscle quantity only. Grip strength and physical performance were unavailable, so low SMI denoted low muscle index or low muscle mass, not a clinical diagnosis of sarcopenia.

How many patients and deaths contributed to the adjusted muscle-index survival analysis in extensive-stage small-cell lung cancer?

The primary OS Cox model included 79 patients and 55 deaths. It used available complete cases without imputing missing data.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free